Multi-arm polyethylene glycol drug conjugate as well as preparation method and application thereof
By developing ultrasonic sensitive multi-arm polyethylene glycol carrier coupled to SN38, ultrasonic excitation is used to achieve accurate drug release, solving the problems of poor water solubility and high toxicity of SN38 in pancreatic cancer treatment, and improving the therapeutic effect and safety.
Patent Information
- Application Number
- CN202411201479.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-29
- Publication Date
- 2024-11-29
AI Technical Summary
The application of SN38 in pancreatic cancer treatment is limited by its poor water solubility and high system toxicity, which leads to poor treatment effect and significant side effects, and low targeted delivery efficiency of tumor cells.
Develop an ultrasonic sensitive multi-arm polyethylene glycol carrier, which combines SN38 with multi-arm polyethylene glycol through chemical coupling reaction to form a multi-arm polyethylene glycol drug conjugate, and achieves the accuracy of the drug under ultrasonic excitation. Release and increase local tumor concentration.
It enhances anti-tumor activity, reduces the toxic effect on normal tissues, improves the targeting and efficiency of treatment, and provides a more effective and safer pancreatic cancer treatment option.
Smart Images

Figure CN119033948A_ABST
Abstract
Description
Technical Field
[0001] The present application belongs to the field of medical technology, and in particular relates to a multi-arm polyethylene glycol drug conjugate and a preparation method and application thereof. Background Art
[0002] Pancreatic cancer is a highly malignant tumor with a low survival rate and difficult treatment. Since pancreatic cancer is often discovered in the late stage, treatment options are limited, and the effects of conventional treatments such as surgery, radiotherapy, and chemotherapy are usually unsatisfactory. Therefore, the development of new treatment strategies is urgently needed. SN38 (7-ethyl-10-hydroxycamptothecin), as an active metabolite of irinotecan (CPT-11), is an effective topoisomerase inhibitor and has been used to treat a variety of cancers, including colorectal cancer, blood cancer, and pancreatic cancer. However, the clinical application of SN38 is limited by its poor water solubility and high systemic toxicity. In addition, the targeted delivery efficiency of SN38 to tumor cells is low, resulting in poor therapeutic effects and significant side effects.
[0003] This application aims to address the limitations of the application of SN38 in the treatment of pancreatic cancer by developing an ultrasound-sensitive multi-arm polyethylene glycol carrier to increase its effective concentration locally in the tumor by coupling SN38, thereby enhancing its anti-tumor activity while reducing its toxic effects on normal tissues. Summary of the invention
[0004] Based on the first aspect of the present application, a multi-arm polyethylene glycol drug conjugate is provided, which has the following structural formula:
[0005]
[0006] Wherein, t is an integer and t≥2; Z is a coupling structure containing a chemical bond, and the chemical bond includes an ester bond, an amide bond and a disulfide bond.
[0007] In at least one embodiment, the chemical structural formula is preferably:
[0008]
[0009] Based on the second aspect of the present application, a method for preparing the above-mentioned multi-arm polyethylene glycol drug conjugate is provided, comprising:
[0010] Selecting multi-arm polyethylene glycol with a molecular weight ranging from 2000Da to 40000Da;
[0011] In an anhydrous environment, multi-arm polyethylene glycol was combined with 7-ethyl-10-hydroxycamptothecin through a chemical coupling reaction.
[0012] In at least one embodiment, the multi-arm polyethylene glycol is four-arm polyethylene glycol.
[0013] In at least one embodiment, the chemical coupling reaction is a coupling through a chemical bond structure containing a disulfide bond.
[0014] In at least one embodiment, the particle size of the multi-arm polyethylene glycol drug conjugate is in the range of 10 to 200 nm.
[0015] In at least one embodiment, the preparation method specifically comprises the following steps:
[0016] 1) dissolving NH2-SS-COOH in a mixture of H2O and DMF (N,N-dimethylformamide), adding Na2CO3 and Fmoc-Osu (fluorenylmethoxycarbonyl succinimide), mixing and reacting, filtering, extracting the reaction product, and obtaining a crude product;
[0017] 2) dissolving the crude product, SN38 (7-ethyl-10-hydroxycamptothecin), DCC (dicyclohexylcarbodiimide), and DMAP (4-dimethylaminopyridine) in dichloromethane, mixing and reacting, filtering, extracting the reaction product, and purifying by flash column chromatography to obtain a white solid product;
[0018] 3) dissolving the white solid product in a mixture of DMF and piperidine, removing the solvent under reduced pressure after mixed reaction, and purifying by rapid column chromatography to obtain a yellow solid product;
[0019] 4) dissolving the yellow solid product in DMF, adding four-arm polyethylene glycol, mixing to complete the chemical coupling reaction, removing the solvent under reduced pressure, dissolving and extracting with water, and then chromatographically purifying, precipitating with ether and freeze-drying to obtain the final product.
[0020] Furthermore, in step 1), the process of extracting the reaction product is: first extracting with ethyl acetate, acidifying the aqueous phase with hydrochloric acid to pH=2, then extracting the aqueous phase with dichloromethane, combining the organic phases of the two extractions, washing with saturated brine, drying with sodium sulfate, filtering, and removing the solvent under reduced pressure.
[0021] Furthermore, in step 2), the process of extracting the reaction product is: first extracting with water, extracting the aqueous phase with dichloromethane, combining the organic phases of the two extractions, drying with sodium sulfate, filtering, and removing the solvent under reduced pressure.
[0022] Furthermore, in step 2), the solvent used for the rapid column chromatography purification is DCM / MeOH, and the volume ratio thereof is DCM:MeOH=20:1.
[0023] Furthermore, in step 3), the solvent used for the rapid column chromatography purification is DCM / MeOH, and the volume ratio thereof is DCM:MeOH=5:1.
[0024] Furthermore, in step 4), the chromatographic purification uses GPC PS-beads-X1 filler.
[0025] Based on the third aspect of the present application, provided is the use of the above-mentioned multi-arm polyethylene glycol drug conjugate in the preparation of a drug for treating pancreatic cancer.
[0026] In at least one embodiment, the drug at least contains the multi-arm polyethylene glycol drug, and may further contain pharmaceutically acceptable excipients.
[0027] In at least one embodiment, the dosage form of the drug may include granules, powders, tablets, capsules, pills, oral solutions or injections.
[0028] According to the fourth aspect of the present application, a controlled release method for a drug for treating pancreatic cancer is provided, comprising:
[0029] Selecting the multi-arm polyethylene glycol drug conjugate as a drug for treating pancreatic cancer;
[0030] The multi-arm polyethylene glycol drug conjugate was treated with ultrasound.
[0031] In at least one embodiment, the ultrasonic treatment time is 5 to 20 minutes.
[0032] Compared with the prior art, the present invention achieves at least the following beneficial effects:
[0033] 1. This application develops a new type of multi-arm polyethylene glycol carrier, and after coupling SN38 with the carrier, an ultrasound-sensitive pancreatic cancer therapeutic drug is prepared. The carrier can enhance the therapeutic effect on pancreatic cancer under the stimulation of ultrasound and achieve rapid drug release. This ultrasound sensitivity property allows SN38 to be accurately released in the tumor area under ultrasound guidance, increasing the local concentration of the drug and thus enhancing the therapeutic effect.
[0034] 2. The multi-arm polyethylene glycol drug conjugate designed in this application has a chemical structure with high drug loading and good biocompatibility. Through chemical bonding, SN38 and multi-arm PEG form a stable prodrug form, which maintains a relatively stable state in serum and reduces nonspecific release and side effects in the body.
[0035] 3. Utilizing the directional nature of ultrasound, the controlled release method for treating pancreatic cancer drugs in this application can enhance the precise positioning of pancreatic cancer tumors and drug release, and improve the targeting and efficiency of treatment. Compared with traditional systemic treatments, it has higher safety and efficacy, and enhances anti-tumor activity and reduces side effects. By improving the solubility and bioavailability of SN38, and its concentrated release in the tumor area, this application can significantly improve its anti-tumor activity while reducing toxicity and side effects to normal tissues, providing a more effective and safer treatment option for pancreatic cancer patients. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 , the structural formula of the multi-arm polyethylene glycol drug conjugate (4arm-PEG-SN38) provided in the examples of the present application.
[0037] Figure 2 , a flow chart of the method for preparing 4arm-PEG-SN38 provided in the examples of the present application.
[0038] Figure 3 、NMR of drug molecules 1 H-NMR spectrum.
[0039] Figure 4 , NMR MALDI TOF spectrum of drug molecules.
[0040] Figure 5 , Malvern nanoparticle size analyzer particle size test image and transmission electron microscope (TEM) image of the multi-arm polyethylene glycol drug conjugate.
[0041] Figure 6 , drug release diagram of multi-arm polyethylene glycol drug conjugate under in vitro ultrasound.
[0042] Figure 7 , the killing effect on tumor cells in in vitro experiments.
[0043] Figure 8 , anti-tumor effect diagram of in vivo experiment. DETAILED DESCRIPTION
[0044] The present application will be described in detail below with reference to the exemplary embodiments or experimental examples in the accompanying drawings. However, it should be understood that the present application can be implemented in a variety of different forms and should not be construed as being limited to the embodiments described herein. These embodiments are provided here to make the disclosure of the present application more complete and to fully convey the concept of the present application to those skilled in the art.
[0045] Example 1. Multi-arm polyethylene glycol drug conjugate and preparation method thereof.
[0046] refer to Figure 2, the preparation of a multi-arm polyethylene glycol drug conjugate comprises the following steps:
[0047] 1) NH2-SS-COOH (1 g, 5.5 mmol, 1.0 eq) was dissolved in a 1:1 mixture of H2O and DMF (38.5 mL), and Na2CO3 (5.0 eq) and Fmoc-OSu (1.5 eq) were added and stirred at room temperature for 18 h. The mixture was filtered and extracted with ethyl acetate (2 x 50 mL). The aqueous phase was then acidified to pH 2 with 4 M hydrochloric acid and extracted with dichloromethane (3 x 70 mL). The combined organic phase was washed with saturated brine (30 mL), dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure to obtain a crude product (1.25 g, 3.1 mmol, 56% yield).
[0048] 2) In a 100 ml dry Schlenk flask, the crude product of step 1) (1.25 g, 3.1 mmol, 1.0 eq.), SN38 (1.5 g, 3.84 mmol, 1.2 eq), DCC (960 mg, 4.65 mmol, 1.5 eq) and DMAP (38 mg, 0.31 mmol, 0.1 eq) were added and dissolved in dichloromethane (2 mL / mmol). The resulting solution was stirred at room temperature for 16 hours. After the mixture was filtered, it was extracted with water (10 mL). Then, the aqueous phase was extracted with dichloromethane (2 x 10 mL). The combined organic phase was dried over sodium sulfate, filtered, and the solvent was removed under reduced pressure. The resulting mixture was purified by flash column chromatography (DCM: MeOH = 20: 1) to obtain a white solid product (1.7 g, 2.19 mmol, 71% yield).
[0049] 3) In a 100 ml dry Schlenk flask, add the white solid product of step 2) (1.7 g, 2.19 mmol, 1.0 eq) dissolved in DMF / piperidine (9:1, 5 mL). The resulting solution was stirred at room temperature for 16 hours. The solvent was removed under reduced pressure. The resulting mixture was purified by flash column chromatography (DCM: MeOH = 5:1) to obtain a yellow solid product (1.11 g, 2 mmol, 90% yield).
[0050] 4) In a 100 ml dry Schlenk flask, add the yellow solid product (1.11 g, 2 mmol, 40 eq) of step 3) and dissolve it in DMF (5 mL), and add 4arm-PEG-SC (20 kDa, 1 g, 0.05 mmol, 1 eq). The resulting solution was stirred at room temperature for 72 h. The solvent was removed under reduced pressure. The resulting mixture was dissolved and extracted with water and then chromatographed on GPCPS-beads-X1 filler, and lyophilized by ether precipitation to obtain a white product 4arm-PEG-SN38 (0.7 g, 2 mmol, 90% yield).
[0051] The obtained 4arm-PEG-SN38 has a chemical structure as shown Figure 1 shown; 1 H-NMR and MALDI TOF images are shown in Figure 3 and Figure 4 shown. Specifically, Figure 3 NMR of drug molecules 1 H-NMR spectrum, after the molecules are purified by molecular sieve, small molecules have been removed, 1 H-NMR still clearly shows the characteristic nuclear magnetic peaks of the small molecule, and the relevant nuclear magnetic peaks of the small molecule shift, verifying the correctness of the chemical structure. Figure 4 This is the NMR MALDI TOF spectrum of the drug molecule. From the spectrum, we can clearly see that the molecular weight of the PEG molecule ranges from 21kDa ( Figure 4 c1) increased to about 23 kDa ( Figure 4 c2), the molecular weight increases by about 2 kDa, while the molecular weight of the product obtained in this example is 555.15, and the molecular weight of the four molecules is 20 kDa, from which it can be judged that the small molecule is basically coupled to the PEG molecule. 1 From the H-NMR and MALDI TOF spectra, characteristic peaks and molecular weight migration can be observed, further confirming the successful synthesis and purity of 4arm-PEG-SN38. From the spectra, we can clearly see that 4arm-PEG-SN38 has been successfully prepared.
[0052] The Malvern nanoparticle size test image and transmission electron microscope (TEM) image of the obtained 4arm-PEG-SN38 are shown in Figure 5As shown. The particle size test results show that the size of the nanoparticles ranges from 100 to 200 nm, and the TEM image further verifies this result. Both the particle size test graph and the TEM image show that multi-arm polyethylene glycol SN38 forms uniform nanoparticles, and the particle size is mainly concentrated in the range of 100 to 200 nm. This particle size is suitable for drug delivery systems and can be more effectively accumulated in tumor tissues through the EPR effect (Enhanced Permeability and Retention Effect), thereby improving the therapeutic effect.
[0053] Example 2: In vitro drug release experiment.
[0054] The multi-arm polyethylene glycol drug conjugate prepared in Example 1 was prepared into a prodrug solution according to a conventional method. The prodrug solution containing 10 mM phosphate buffer (PBS) was placed in a dialysis bag, and the drug was released by ultrasound. The change in the ultraviolet absorbance of the released solution at 264 nm was observed. The results are as follows: Figure 6 As shown. HPLC analysis showed that after 5 minutes of ultrasonic treatment, about 1% of the active drug was released in the form of small molecules. Further extending the ultrasonic time to 20 minutes, the release amount was about 20%, showing a time-dependent activation characteristic. The drug release graph showed that ultrasound can effectively trigger the drug release of multi-arm polyethylene glycol SN38, and the release amount is positively correlated with the ultrasonic time. This ultrasound-triggered release mechanism allows the drug to be released at a specific time and location with good controllability.
[0055] Example 3: In vitro anti-tumor experiment.
[0056] The multi-arm polyethylene glycol drug conjugate prepared in Example 1 was used for in vitro experiments. The experiment was divided into four groups: PBS group (PBS), SN38 group (SN38), polyethylene glycol-SN38 group (PEG-SS-SN38), and ultrasound + polyethylene glycol-SN38 group (US + PEG-SS-SN38). The experimental method is: PNAC-1 cells were seeded in a 96-well cell culture plate at a density of 5000 cells per well. After culturing for 24 hours, the corresponding drugs were added according to the grouping and incubated for 24 and 48 hours. Then, 20 μL of CCK-8 solution was added to each well and incubated for another 4 hours. After the incubation, the absorbance was measured at a wavelength of 450 nm using a Bio-Rad microplate reader, and the cell viability was calculated by the following formula:
[0057] Cell viability (%) = [(As-Ab) / (Ac-Ab)] × 100;
[0058] Wherein, As is the absorbance of the experimental well (the absorbance of the well containing cells, culture medium, CCK-8 and the test compound); Ab is the absorbance of the blank well (the absorbance of the well containing culture medium and CCK-8); Ac is the absorbance of the control well (the absorbance of the well containing cells, culture medium and CCK-8).
[0059] The experimental results are as follows Figure 7 As shown in the figure, ultrasound-sensitive multi-arm polyethylene glycol SN38 (PEG-SN38) has a significant time-dependent killing effect on tumor cells in in vitro experiments. After 24 hours of co-incubation of cells with drugs, the drugs at various dosing concentrations did not show obvious cytotoxicity. This shows that in a short period of time, the killing effect of the drug on tumor cells is weak, which may be related to the accumulation of the drug in the cells and insufficient action time. However, as the incubation time is extended to 48 hours, the experimental data reveal that the killing effect of the drug on tumor cells under different conditions is significantly different. Specifically, the killing effect of PEG-SN38 after 5 minutes of ultrasound pretreatment is the most significant, which is better than PEG-SN38 without ultrasound treatment, which is better than free SN38. This result shows that ultrasound pretreatment can significantly enhance the cytotoxicity of PEG-SN38, which may be due to the fact that ultrasound can increase the permeability of cell membranes, promote the intracellular absorption of drugs and the release of active ingredients. In addition, compared with free SN38, PEG-modified SN38 exhibits higher biocompatibility and better drug stability, further improving the anti-tumor effect. Based on the above experimental results, the following conclusions can be drawn: PEG-SN38 can significantly enhance its anti-tumor cell activity through ultrasonic pretreatment, and its effect is better than that of untreated PEG-SN38 and free SN38.
[0060] Example 4: In vivo anti-tumor experiment.
[0061] The multi-arm polyethylene glycol drug conjugate prepared in Example 1 was used to test the anti-tumor effect in mice. The experiment was divided into six groups: PBS group (PBS), ultrasound group (US), irinotecan group (SN38), ultrasound + irinotecan group (US + SN38), polyethylene glycol-SN38 group (4arm-PEG-SN38), ultrasound + polyethylene glycol-SN38 group (US + 4arm-PEG-SN38). The experimental method is as follows: The animal experiment was approved by the Animal Ethics Committee of Guangxi Medical University (Ethics Number: 202404004). The pancreatic cancer tumor-bearing nude mouse model was established according to the methods of existing literature. In short, 2×10 6PNAC-1 cells were mixed with Matrigel at a ratio of 1:1 and injected subcutaneously into the back of male nude mice aged four to six weeks (nude mice were purchased from the Animal Experiment Center of Guangxi Medical University). Three weeks after the injection, the mice were injected with drugs (equivalent to SN38 10mg / kg equivalent drug, tail vein injection) every three days after the tumor was formed, for a total of 6 times. The tumor size and nude mouse weight were measured every three days, and the longest and shortest parts of the tumor were measured with a vernier caliper. V = 1 / 2ab 2 (a is the major axis, b is the minor axis).
[0062] The experimental results are as follows Figure 8 As shown, in the six groups of experiments, the ultrasound + polyethylene glycol-SN38 group (US + 4arm-PEG-SN38) showed significant anti-tumor effects. Specifically, the ultrasound + polyethylene glycol-SN38 group was significantly better than the other groups in tumor volume inhibition and safety. In contrast, although the group using polyethylene glycol-SN38 alone (4arm-PEG-SN38) showed certain anti-tumor activity, the effect was not as good as the irinotecan group; and although the groups using irinotecan alone and irinotecan + US had certain inhibitory effects, the tumor inhibition effect was relatively weaker than the 4arm-PEG-SN38 + US group, and showed certain toxicity, that is, the weight of mice decreased.
[0063] Statistical analysis showed that the final tumor volume between the 4arm-PEG-SN38+US group and the other groups was significantly different (p<0.05). These results indicate that the combined use of ultrasound and polyethylene glycol-SN38 has a synergistic effect in enhancing anti-tumor efficacy. This synergistic effect may be due to the ultrasound-triggered cleavage of micelles near the tumor and the uncoupling of disulfide bonds by the tumor microenvironment, which promotes the drug release and activation of SN38, thereby increasing the concentration of the drug at the tumor site and enhancing the anti-tumor activity. This discovery provides an important experimental basis for the application of ultrasound-triggered targeted drug delivery systems in tumor treatment, and is expected to provide new ideas for further optimizing anti-tumor treatment strategies.
[0064] The above experimental results show that the multi-arm polyethylene glycol drug conjugate of the present application exhibits excellent drug release and anti-tumor effects both in vivo and in vitro. Its ultrasound-triggered release mechanism enables the drug to be released at a specific time and location, with good targeting and controllability. It is expected to become an efficient and low-toxic tumor treatment method, with the potential for actual clinical application, and is expected to provide a new treatment option for pancreatic cancer patients.
Claims
1. A multi-arm polyethylene glycol drug conjugate, characterized in that: The conjugate has the following chemical structure: Wherein, t is an integer and t≥2; Z is a coupling structure containing a chemical bond, and the chemical bond includes an ester bond, an amide bond and a disulfide bond.
2. The multi-arm polyethylene glycol drug conjugate according to claim 1, characterized in that: The chemical structural formula is:
3. The method for preparing the multi-arm polyethylene glycol drug conjugate according to claim 1, characterized in that: include: Selecting multi-arm polyethylene glycol with a molecular weight ranging from 2000Da to 40000Da; In an anhydrous environment, multi-arm polyethylene glycol was combined with 7-ethyl-10-hydroxycamptothecin through a chemical coupling reaction.
4. The preparation method according to claim 3, characterized in that: The multi-arm polyethylene glycol is four-arm polyethylene glycol.
5. The preparation method according to claim 3, characterized in that: The chemical coupling reaction is a coupling through a chemical bond structure containing a disulfide bond.
6. The preparation method according to claim 3, characterized in that: The steps include: 1) dissolving NH2-SS-COOH in a mixture of H2O and DMF, adding Na2CO3 and Fmoc-OSu, mixing and reacting, filtering, extracting the reaction product, and obtaining a crude product; 2) dissolving the crude product, 7-ethyl-10-hydroxycamptothecin, DCC and DMAP in dichloromethane, mixing and reacting, filtering, extracting the reaction product, and purifying by rapid column chromatography to obtain a white solid product; 3) dissolving the white solid product in a mixture of DMF and piperidine, removing the solvent under reduced pressure after mixed reaction, and purifying by rapid column chromatography to obtain a yellow solid product; 4) dissolving the yellow solid product in DMF, adding four-arm polyethylene glycol, mixing to complete the chemical coupling reaction, removing the solvent under reduced pressure, dissolving and extracting with water, and then chromatographically purifying, precipitating with ether and freeze-drying to obtain the final product.
7. The preparation method according to claim 6, characterized in that: In step 1), the process of extracting the reaction product is: first extracting with ethyl acetate, acidifying the aqueous phase with hydrochloric acid to pH=2, then extracting the aqueous phase with dichloromethane, combining the organic phases of the two extractions, washing with saturated brine, drying with sodium sulfate, filtering, and removing the solvent under reduced pressure; In step 2), the process of extracting the reaction product is: first extracting with water, extracting the aqueous phase with dichloromethane, combining the organic phases of the two extractions, drying with sodium sulfate, filtering, and removing the solvent under reduced pressure.
8. The preparation method according to claim 1, characterized in that: The particle size of the multi-arm polyethylene glycol drug conjugate is in the range of 10 to 200 nm.
9. Use of the multi-arm polyethylene glycol drug conjugate according to any one of claims 1 to 2 or the multi-arm polyethylene glycol drug conjugate prepared by the preparation method according to any one of claims 3 to 8 in the preparation of a drug for treating pancreatic cancer.
10. A controlled release method for a drug for treating pancreatic cancer, comprising: Selecting the multi-arm polyethylene glycol drug conjugate according to any one of claims 1 to 2 or the multi-arm polyethylene glycol drug conjugate prepared by the preparation method according to any one of claims 3 to 8 as a drug for treating pancreatic cancer; The multi-arm polyethylene glycol drug conjugate was treated with ultrasound.
